PROFOUND MEDICAL CORP. Revenue from Contract with Customer, Excluding Assessed Tax
PROFOUND MEDICAL CORP. (PROF) reported Revenue from Contract with Customer, Excluding Assessed Tax of $5.06 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-11-13
- PROFOUND MEDICAL CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $5.06M, a 99.02% increase year-over-year.
- PROFOUND MEDICAL CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $1.98M, a 1.43% increase year-over-year.
- PROFOUND MEDICAL CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $2.34M, a 92.04% increase year-over-year.
- PROFOUND MEDICAL CORP. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $4.03M.
- PROFOUND MEDICAL CORP. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $9.74M, a 65.11% increase from fiscal 2023.
- PROFOUND MEDICAL CORP. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $5.90M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-09-30 | $5.06M 10-Q · filed 2025-11-13 | $7.04M derived: sum of 2 quarters · filed 2025-11-13 | $9.38M 10-Q · filed 2025-11-13 | $13.41M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | $1.98M 10-Q · filed 2025-08-14 | $4.32M 10-Q · filed 2025-08-14 | $8.35M derived: sum of 3 quarters · filed 2025-08-14 | $10.89M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | $2.34M 10-Q · filed 2025-05-08 | $6.37M derived: sum of 2 quarters · filed 2025-05-08 | $8.91M derived: sum of 3 quarters · filed 2025-11-13 | $10.86M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $6.57M derived: sum of 2 quarters · filed 2025-11-13 | $8.52M derived: sum of 3 quarters · filed 2025-11-13 | $9.74M 10-K · filed 2025-03-07 |
| 2024-09-30 | $2.54M 10-Q · filed 2025-11-13 | $4.50M derived: sum of 2 quarters · filed 2025-11-13 | $5.71M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $1.95M 10-Q · filed 2025-08-14 | $3.17M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $1.22M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $5.90M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |